The platform

Precision in the
way medicine moves.

Drug delivery technologies being developed for sustained, non-opioid approaches to acute pain.

Explore the pipeline
Contextual laboratory scientist using a microscope
The lead gel program combines extended-release bupivacaine with an injectable delivery approach
Alevatrix™

Designed around
the days after surgery.

The lead gel program combines extended-release bupivacaine with an injectable delivery approach. The company’s duration observations come from large-animal models; they are not established patient outcomes.

View current company information
01 / Candidate program

Alevatrix™

Extended-release bupivacaine gel being developed for postoperative pain.

Intended prefilled syringe format

Investigational. Safety and efficacy in patients are not established by this concept.

Official pipeline information
02 / Candidate program

RBL-001

Extended-release bupivacaine solution under development for local or regional anesthesia and acute or dental pain.

Investigational solution program

Investigational. Safety and efficacy in patients are not established by this concept.

Official pipeline information
Official Rebel Medicine photograph of a scientist with a test tube
A closer perspective

Translate the idea. Keep the science clear.

A platform for
collaboration.

Discuss research and development opportunities with Rebel’s business development team.

Explore partnering